
TechTalk: Hitting your toughest targets with Optimer® binders
Friday, September 25 at 15:30 BST | 16:30 CEST | 10:30 EDT | 07:30 PDT
Antibodies remain the default affinity reagent for many workflows, but some targets (including small molecules, membrane proteins, and multi-subunit complexes) can be difficult to generate effective binders against. Lot-to-lot variability, lengthy development timelines, and limited control over binding and elution conditions can create additional challenges.
In this SelectScience® TechTalk, discover how Optimer® binders provide an alternative to antibodies, engineered from the outset around the target, application, and assay environment. Learn how Optimers are being used to address targets that have historically proved challenging for antibodies, while the same discovery platform delivers application-ready reagents for ELISA, IHC, flow cytometry, biosensing, affinity purification, and IP-MS workflows.
Explore how tuneable affinity, reversible and gentle elution, chemical stability, and consistent lot-to-lot performance can help researchers overcome common reagent limitations and build more robust, reproducible assays.
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
TechTalk details
- Cost: Free to attend
- Location: Online
- Duration: 20 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available
Speakers

Who should attend?
Research and development specialists working in biotech, pharmaceutical companies, and academia who are seeking higher-performance reagents or working with challenging targets for which antibodies are unavailable or have failed to deliver reliable results.
What will this webinar cover?
Join the TechTalk to get answers to these questions:
- Which Optimer development approach best suits your target and application?
- How do Optimer binders compare with antibodies in real assay formats?
- How can Optimers address challenging targets such as small molecules and membrane proteins?
- What does the custom Optimer development process include?
- How can tuneable affinity and gentle elution improve assay reproducibility?
